医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

MOIDA Distributes Globally Korean Clean Beauty Brand ‘MELLISSOM’

2021年01月19日 PM10:00
このエントリーをはてなブックマークに追加


 

NAMYANGJU, South Korea

MOIDA, a Korean distributor, commenced global distribution of ‘Daily Calming Skin Pad.’ Daily Calming Skin Pad is a product of ‘MELLISSOM,’ which is a clean beauty brand of Ipia Cosmetic, a partner of the company.

Daily Calming Skin Pad, a dermatologically tested product of MELLISSOM, does not contain paraben, animal-derived ingredients, mineral oil, synthetic coloring, or artificial fragrance. The premium pad developed using 100% cotton fabric without bleaching or fluorescence brightening agents is safe for use on sensitive skin. In addition, cypress water contained in this product comfortably soothes the skin.

“The popularity of clean beauty cosmetics containing healthy ingredients is rising in the global market, such as the U.S. and Europe,” said a MELLISSOM insider. He explained, “With the demand for hypoallergenic products increasing in line with the necessity to wear face masks over a long period of time due to the COVID-19 pandemic, the clean beauty market is growing at a fast rate.”

Clean beauty products are cosmetics that convey the value of “ethical consumption” to promote environmental and animal protection and eliminate the use of ingredients that are harmful to the human body, such as paraben and avobenzone. In a questionnaire survey, nine out of ten female consumers responded to “choose cosmetics that are helpful for the society and environment.” As such, a growing number of consumers are reflecting their values and beliefs in their consumption activities.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005433/en/

CONTACT

MOIDA

Sung-min Kim +82-31-595-4615

moida@kmoida.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists